Results 221 to 230 of about 96,616 (241)
Some of the next articles are maybe not open access.
Natalizumab for the treatment of highly active multiple sclerosis: risks and benefits
British Journal of Neuroscience Nursing, 2019This article discusses the history of natalizumab (Tysabri), the first monoclonal antibody used to treat multiple sclerosis. It reviews how the medication's difficult beginnings and controversial past have changed how this treatment is monitored. The article looks at the role of clinicians in maintaining patient safety, the benefits and risk profile ...
openaire +1 more source
S.S. Korsakov Journal of Neurology and Psychiatry
Objective. To evaluate the effect of discontinuation or prolongation of DMT on the activity of the disease during pregnancy and in the postpartum period in patients with aggressive MS from the Moscow region. Material and methods. The study included female patients with an aggressive course of MS receiving DMT at the time of pregnancy. The patients were
D.M. Yakushin +3 more
openaire +2 more sources
Objective. To evaluate the effect of discontinuation or prolongation of DMT on the activity of the disease during pregnancy and in the postpartum period in patients with aggressive MS from the Moscow region. Material and methods. The study included female patients with an aggressive course of MS receiving DMT at the time of pregnancy. The patients were
D.M. Yakushin +3 more
openaire +2 more sources
Natalizumab for Moroccan Patients with Highly Active Multiple Sclerosis
Multiple Sclerosis and Related Disorders, 2023Youssouf Ben Moh, Ahmed Bourazza
openaire +1 more source
Predictive Factors for the Development of Highly Active Multiple Sclerosis
Multiple Sclerosis and Related Disorders, 2023Zmantar Saoussen +5 more
openaire +1 more source
Fingolimod in Highly Active Pediatric Multiple Sclerosis
Neuropediatrics, 2016P. Huppke +3 more
openaire +1 more source
S.S. Korsakov Journal of Neurology and Psychiatry
Objective. To assess the efficacy and safety of cladribine in patients with highly active multiple sclerosis (MS) in the Moscow region. Material and methods. The analysis was based on data from 62 patients treated with cladribine between March 2021 and January 2024.
T.I. Yakushina +3 more
openaire +2 more sources
Objective. To assess the efficacy and safety of cladribine in patients with highly active multiple sclerosis (MS) in the Moscow region. Material and methods. The analysis was based on data from 62 patients treated with cladribine between March 2021 and January 2024.
T.I. Yakushina +3 more
openaire +2 more sources
Natalizumab treatment for highly active pediatric multiple sclerosis (P1.352)
Neurology, 2017Anat Achiron +3 more
openaire +1 more source